Torley Helen 4

4 · HALOZYME THERAPEUTICS, INC. · Filed Mar 4, 2026

Insider Transaction Report

Form 4

Period: 2026-03-02

HALOZYME THERAPEUTICS, INC.HALO

Torley Helen

DirectorPRESIDENT AND CEO

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-02$12.07/sh+20,000$241,400→ 787,780 total
Sale
Common Stock
[F1][F2]
2026-03-02$69.20/sh−4,100$283,708→ 783,680 total
Sale
Common Stock
[F1][F3]
2026-03-02$69.80/sh−15,322$1,069,460→ 768,358 total
Sale
Common Stock
[F1][F4]
2026-03-02$70.46/sh−578$40,726→ 767,780 total
Exercise/Conversion
Common Stock
[F1]
2026-03-03$12.07/sh+20,000$241,400→ 787,780 total
Sale
Common Stock
[F1][F5]
2026-03-03$68.85/sh−13,481$928,167→ 774,299 total
Sale
Common Stock
[F1][F6]
2026-03-03$69.33/sh−6,519$451,982→ 767,780 total
Exercise/Conversion
Common Stock
[F1]
2026-03-04$12.07/sh+10,000$120,700→ 777,780 total
Sale
Common Stock
[F1][F7]
2026-03-04$69.94/sh−7,329$512,620→ 770,451 total
Sale
Common Stock
[F1][F8]
2026-03-04$70.94/sh−2,671$189,494→ 767,780 total
Exercise/Conversion
Option to Purchase Common Stock
[F1][F9]
2026-03-02$12.07/sh−20,000$241,400→ 181,923 total
Exercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying)
Exercise/Conversion
Option to Purchase Common Stock
[F1][F9]
2026-03-03$12.07/sh−20,000$241,400→ 161,923 total
Exercise: $12.07Exp: 2027-02-22→ Common Stock (20,000 underlying)
Exercise/Conversion
Option to Purchase Common Stock
[F1][F9]
2026-03-04$12.07/sh−10,000$120,700→ 151,923 total
Exercise: $12.07Exp: 2027-02-22→ Common Stock (10,000 underlying)

Footnotes (9)

[F1]The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025 in accordance with Rule 10b5-1. The sales of common shares reported on this Form 4 represent shares that were acquired following exercise of stock options with a ten-year term expiring in February 2027.
[F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.375 to $69.370. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.380 to $70.340. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.380 to $70.620. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F5]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.220 to $69.210. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F6]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.220 to $69.520. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F7]Represents a weighted average sales price per share. The shares were sold at prices ranging from $69.400 to $70.390. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F8]Represents a weighted average sales price per share. The shares were sold at prices ranging from $70.400 to $71.360. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F9]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was February 22, 2017.

Signature

/s/ James R. Oehler, Attorney-in-Fact|2026-03-04

Documents

1 file

4
wk-form4_1772668573.xmlPrimary
FORM 4